Successful prior treatment with dasatinib followed by stem cell transplantation in a patient with CML in blastic crisis with a BCR–ABL mutation
- 220 Downloads
- 2 Citations
Abstract
We report a case of imatinib- and nilotinib-resistant Ph-positive chronic myeloid leukemia (CML) in blast crisis in which successful pretreatment with dasatinib with cord blood transplantation resulted in molecular remission. Before dasatinib therapy, the patient was found to have a F359V BCR–ABL mutation. He was treated with dasatinib for just 16, 19 days before allogeneic stem cell transplantation. This successful case indicates that reduction of tumor burden by second-generation tyrosine kinase inhibitors, in combination with stem cell transplantation, might be effective to treat CML, even in the advanced phase.
Keywords
Dasatinib Chronic myeloid leukemia Stem cell transplantation BCR/ABL mutationsNotes
Acknowledgments
We are grateful to Roderick J. Turner and Professor J Patrick Barron of the Department of International Medical Communications, Tokyo Medical University, for their review of this manuscript.
References
- 1.Goldman JM. How I treat chronic myeloid leukemia in the imatinib era. Blood. 2007;110:2828–37.CrossRefPubMedGoogle Scholar
- 2.Shimoni A, Leiba M, Schleuning M, et al. Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT toxicity in patients with chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemia. Leukemia. 2009;23:190–4.CrossRefPubMedGoogle Scholar
- 3.Yamamoto M, Kakihana K, Ohashi K, et al. Serial monitoring of T315I BCR-ABL mutation by Invader assay combined with RT-PCR. Int J Hematol. 2009;89:482–8.CrossRefPubMedGoogle Scholar
- 4.Tojo A, Usuki K, Urabe A, et al. A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or–intolerant Ph + CML or relapsed/refractory Ph + ALL. Int J Hematol. 2009;89:679–88.CrossRefPubMedGoogle Scholar
- 5.Marin D, Milojkovic D, Olavarria E, et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood. 2008;112:4437–44.CrossRefPubMedGoogle Scholar
- 6.O’Hare T, Eide CA, Deininger MW. New Bcr–Abl inhibitors in chronic myeloid leukemia: keeping resistance in check. Export Opin Investig Drugs. 2008;17:865–78.CrossRefGoogle Scholar
- 7.Milojkovic D, Bua M, Apperley JF, et al. Prediction of cytogenetic response to second generation TKI therapy in CML chronic phase patients who have failed imatinib therapy and early identification of factors that influence survival. ASH Abstracts. 2008; Abst 332.Google Scholar
- 8.Ottmann O, Dombret H, Martinelli G, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood. 2007;110:2309–15.CrossRefPubMedGoogle Scholar
- 9.García-Muñoz R, Galar A, Moreno C, et al. Parvovirus B19 acute infection and a reactivation of cytomegalovirus and herpesvirus 6 in a chronic myeloid leukemia patient during treatment with dasatinib (BMS-354825). Leuk Lymphoma. 2007;48:2461–4.CrossRefPubMedGoogle Scholar
- 10.Redaelli S, Piazza R, Rostagno R, et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol. 2009;20:469–71.Google Scholar
- 11.Breccia M, Palandri F, Iori AP, et al. Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib. Leuk Res. 2009; 28. (ahead of print) doi: 10.1016/j.leukres.2009.04.036.